Kyntra Bio
KYNB
187 hedge funds and large institutions have $3.39B invested in Kyntra Bio in 2018 Q3 according to their latest regulatory filings, with 20 funds opening new positions, 52 increasing their positions, 73 reducing their positions, and 23 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 4 → 4 (0)
0.45% less ownership
Funds ownership: 3.1% → 2.65% (-0.45%)
3% less funds holding
Funds holding: 192 → 187 (-5)
13% less first-time investments, than exits
New positions opened: 20 | Existing positions closed: 23
16% less capital invested
Capital invested by funds: $4.05B → $3.39B (-$654M)
21% less call options, than puts
Call options by funds: $32.9M | Put options by funds: $41.4M
29% less repeat investments, than reductions
Existing positions increased: 52 | Existing positions reduced: 73
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
First Trust Advisors
Wheaton,
Illinois
|
+$27.9M |
| 2 |
CS
Candriam SCA
Strassen, Luxembourg,
Luxembourg
|
+$13.7M |
| 3 |
Man Group
London,
United Kingdom
|
+$9.53M |
| 4 |
State Street
Boston,
Massachusetts
|
+$8.48M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$7.71M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$486M |
| 2 |
PC
PointState Capital
New York
|
-$50.7M |
| 3 |
FCM
Farallon Capital Management
San Francisco,
California
|
-$19.9M |
| 4 |
Goldman Sachs
New York
|
-$14.5M |
| 5 |
Prudential Financial
Newark,
New Jersey
|
-$12.7M |
KYNB Hedge Fund Activity: Q3 2018 in Review
187 of the 4,390 institutional investors tracked by Wall St. Rank reported a position in Kyntra Bio (KYNB) for Q3 2018, worth a combined $3.39B — down 16% from $4.05B a quarter earlier.
Sellers outnumbered buyers: 23 funds closed out of KYNB and 20 opened new positions — a net loss of 3 holders — while 73 trimmed existing stakes and 52 added.
The largest buyer was First Trust Advisors, adding an estimated $27.9M. The largest seller was Fidelity Investments, cutting an estimated $486M.
- 187 institutional investors held Kyntra Bio (KYNB) as of Q3 2018, down from 192 in Q2 2018.
- Funds reported $3.39B of Kyntra Bio stock for Q3 2018, down 16% quarter-over-quarter.
- 20 funds opened new Kyntra Bio positions in Q3 2018 and 23 closed out, a net change of -3 holders.
- The largest Kyntra Bio buyer in Q3 2018 was First Trust Advisors, an estimated $27.9M added.
- The largest Kyntra Bio seller in Q3 2018 was Fidelity Investments, an estimated $486M sold.
Based on aggregated 13F filings for Q3 2018.